RESUMEN
PURPOSE: The aim of this study is to analyze mortality trends of HPV-related cancers in Spain by gender, during the period 1996-2010, and make predictions until the year 2025. METHODS: All deaths registered as cervical cancer were registered (ICD-10 code: C53), as well as vulvar and vaginal (C51 and C52), anal (C21), penile (C60), and oropharyngeal (C02, C09, C10). Adjusted rate calculations for each year were used to study the trends through the regression program Joinpoint. Predictions were made using the Nordpred program, utilizing the age-period-cohort model. RESULTS: In men, a statistically significant increase was observed in mortality by anal cancer, a reduction was observed in oropharyngeal cancer mortality and penile cancer rates were stable. In women, a statistically significant decreasing trend was observed for cervical, vulvar and vaginal cancers. In the predictions, the annual change relative to risk or population changes (size and structure) revealed a reduction in death risk by oropharyngeal cancer in men, and a reduction in death risk by anal cancer in women, although stable adjusted rates were verified for anal cancer in women. CONCLUSIONS: Although an increase was identified in the number of deaths for both genders, rates indicate gender differences in the trends, with increased rates for anal cancer and reduced rates for oropharyngeal cancer in men. Women presented reduced rates for cervical, vulvar, and vaginal cancers. For penile cancer and anal cancer in women, stable trends were verified.
Asunto(s)
Neoplasias/mortalidad , Neoplasias/virología , Infecciones por Papillomavirus/complicaciones , Infecciones por Papillomavirus/mortalidad , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Niño , Preescolar , Costo de Enfermedad , Femenino , Predicción , Humanos , Lactante , Recién Nacido , Masculino , Persona de Mediana Edad , Mortalidad/tendencias , Sistema de Registros , España/epidemiología , Adulto JovenRESUMEN
OBJECTIVE: estimate colorectal cancer incidence and prevalence in, based on mortality and survival data from the period 1998-2007, and provide projections of incidence, prevalence and mortality until the year 2022. METHODS: general and colorectal cancer mortality rates were obtained from the National Statistics Institute and survival data was obtained from the EUROCARE study. Estimations were carried out through the program MIAMOD. The joinpoint program was used to quantify the annual change expected in the projections. RESULTS: in men, an increase in prevalence is expected, from 237.2 (Crude Rate - CR = 303.5) to 237.7 (CR = 412.7) per 100.000 inhabitants/year in 2022. Incidence rates would increase from 48.2 (CR = 61.6) in 2007 to 55.2 (CR = 83.1), and mortality would increase from 22.7 (CR = 29.4) to 26.0 (CR = 39.6) when comparing 2007 and women, a reduction in prevalence is expected from 181.5 (CR = 268.3) to 167.9 (CR = 286.2) cases per 100,000 inhabitants/year. Incidence would change from 25.0 (CR = 38.0) in 2007 to 22.7 (CR = 39.2), and for mortality there is also an expected decrease, from 11.3 (CR =18.0) to 10.3 (CR = 18.5). CONCLUSION: the projections indicate that colorectal cancer in follows an increasing trend in incidence, mortality and prevalencein men, in opposition to corresponding decreasing trends in women.These projections must be considered in order to plan more effective prevention and treatment measures.
Asunto(s)
Neoplasias Colorrectales/epidemiología , Neoplasias Colorrectales/mortalidad , Adulto , Anciano , Anciano de 80 o más Años , Bases de Datos Factuales , Femenino , Predicción , Humanos , Masculino , Persona de Mediana Edad , Prevalencia , Factores Sexuales , España/epidemiología , Análisis de SupervivenciaRESUMEN
A polyclonal serum sample from a lepromatous leprosy (LL) patient, which presented a specific recognition pattern for leprosin, was used to screen a Mycobacterium leprae genomic library constructed with DNA isolated from human lepromas. One clone, designated ML4-1, which expressed a specific antigenic determinant of M. leprae as part of a beta-galactosidase fusion protein, was isolated. The 1.932 bp M. leprae-derived genomic fragment was sequenced, and it had an incomplete open-reading frame shown to code for a 644 amino-acid polypeptide (72.3 kDa). Some partial nucleotide homology to the M. tuberculosis MTCY9C4 cosmid and the M. leprae B1913 cosmid were found. Southern blot assays using the 584 bp Eco RI-Bam HI fragment excised from the ML4-1 clone revealed that this sequence is present only in the M. leprae genome and not in the 24 different mycobacterial DNA tested. Two oligonucleotides based on the genomic sequence were also synthesized and used as amplifiers for a polymerase chain reaction (PCR) test, giving a positive signal exclusively in M. leprae DNA. Furthermore, 32 sequential synthetic peptides, 20 amino-acids long, spanning the entire protein corresponding to the hypothetical ML4-1 clone sequence, were synthesized and evaluated by ELISA. A peptide included in the 221-240 region was significantly recognized by either lepromatous leprosy or healthy tuberculosis contact patient sera. Thus, PCR amplification of this fragment, along with the recognition of its protein sequence by leprosy patient sera, could be a useful tool for a potential diagnostic method in the detection of M. leprae infection in the future.